Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia

Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2009, Pages 268-280

  Kudrin, Alex ^a  

^a Market Tower ^*  (United Kingdom)

Author keywords

China; Clinical trial; Ethnic factors; Harmonization; Japan

Indexed keywords

NEW DRUG;

ARTICLE; CHINA; CLINICAL RESEARCH; DEVELOPED COUNTRY; DRUG MARKETING; DRUG RESEARCH; ETHNICITY; HUMAN; INDONESIA; JAPAN; MALAYSIA; PHILIPPINES; SINGAPORE; SOUTH KOREA; SOUTHEAST ASIA; THAILAND;

ASIA, SOUTHEASTERN; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; INTERNATIONAL COOPERATION; LEGISLATION, DRUG; MARKETING;

EID: 61449129153     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008329557     Document Type: Article

References (19)

1. Espicom. Biopharmaceuticals in South East Asia. Chichester, UK: Espicom ; 2008.
2. Edwards LD, Fletcher AJ, Fox AW, et al. Principles and Practice of Pharmaceutical Medicine. 2 nd ed. London: John Wiley ; 2007.
3. Doi T. The Anatomy of Dependence. Tokyo: Kadansha International; 1973.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical Data E5 (R1). February 5, 1998. http://www.ich.org.
5. The International HapMap Consortium. A haplotype map of the human genome. Nature. 2005 ; 437: 1299-1320.
6. Myrand SP, Sekiguchi K., Man MZ, et al. Pharmacokinetics/ genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharm Ther. 2008 ; 84: 347-361.
7. Ministry of Health and Welfare Notification 660 (June 1985) and Notification of PAB Director General. Acceptance of Data on Clinical Trials Conducted in Foreign Countries: Japan. June 29, 1987.
8. The 5th IFPMA Asian Regulatory Conference. 2008. www.ifpma.org/arc-2008/ fileadmin/pdfs/Conference-report.
9. Buckton AJ, Bisset SL, Myers RE, et al. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother. 2008 ; 62: 1191-1198.
10. East Asian Pharmaceutical Regulatory Symposium. 2008. http://www.2.convention.co.jp/eaprs2008ph/en/agenda/.
11. Pharmaceutical and Medical Devices Agency (PMDA). http://www.pmda.go.jp/.
12. Farrell AT, Papadouli I., Hori A., et al. The advisory process for anticancer drug regulation: a global perspective. Ann Oncol. 2006 ; 17: 889-896.
13. Deng R., Kaltin R. The regulation and approval of new drugs in China. Drug Inf J. 2004 ; 37: 29-39.
14. Gans HK Revolution in Asian drug development: A Korea and Japan experience. www.pharm.kitasato-u.ac.jp/biostatis/presentation2002/Session6/Gans. pps.
15. Min K-I. Biological division of Korean FDA and licensing of biosimilar: 2007. http://www.bioqc.org/1ab.pdf.
16. Pharmaceutical research: drug discovery research at Dr. Reddy's. http://www.drreddys.com/innovations/innovations.htm.
17. Celltrion. http://www.celltrion.com/adminside/info/download.asp?filename= Celltrion-Biosimilar.pdf.
18. Mahboubi A., Shooshtari TH, Faxeli MR, et al. Comparison of immunogenicity in Balb/C mice of commercially available recombinant hepatitis B vaccines in Iran. J Med Sci. 2008 ; 8: 415-419.
19. Schneider CK, Kalinke U. Towards biosimilar monoclonal antibodies. Nat Biotechnol. 2008 ; 26: 985-990.